Table of Contents
Definition and Background of Burkitt Lymphoma
Burkett lymphoma (BL) is an aggressive B-cell non-Hodgkin lymphoma (NHL). It is named after Dr. Denis Burkitt, who described lymphoma in African children (‘African-type’ or ‘endemic’ Burkitt lymphoma). Another type is the ‘sporadic’ or ‘non-endemic’ type that is more common in the Western world.
Epidemiology of Burkitt Lymphoma
The incidence of endemic and sporadic Burkitt lymphoma (BL) vary geographically.
The endemic BL is found in Africa, hence also called ‘African’ Burkitt lymphoma. The highest incidence of BL occurs in children aged 4-7 years, with an estimated incidence of 4-5 cases per 100,000 children annually. BL accounts for one-third to one-half of all childhood cancers in equatorial Africa. Males are twice more commonly affected than females.
The sporadic or non-endemic BL is common in the United States and Western Europe. It comprises 30% of pediatric lymphomas and less than 1% of adult NHLs in the US, with an estimated incidence of 3 cases per million persons annually. The sporadic BL is also more common in males with an M:F of 3-4:1
Etiology and Pathophysiology of Burkitt Lymphoma
The cancerogenic process of BL takes place in the germinal centers of the lymphoid organs (Peyer’s patches, spleen and lymph nodes). In BL, a characteristic genetic mutation is seen i.e. translocation and deregulation of the c-MYC gene (proto-oncogene) on chromosome 8, which is responsible for the development of BL.
In nearly all cases of endemic (African) BL, Epstein-Barr virus infection (the cause of infectious mononucleosis) is found; such a clear association is not found in cases of the sporadic BL.
Histologically, BL manifests as “starry sky” appearance, with the monoclonal proliferation of medium-sized, noncleaved B-cells that are similar in shape and size; they make up a diffuse pattern of tissue engagement.
Clinical Presentation of Burkitt Lymphoma
The Burkitt lymphoma is a very aggressive B-cell lymphoma that presents with rapidly growing cancer masses that have very short doubling times. The constellation of symptoms of BL depends upon the scale of the lesion, CNS involvement, and the effect on contiguous organs.
The endemic (African) BL commonly presents with large mass involving mandible or maxilla. The primary abdominal and bone marrow involvement is less common.
The sporadic BL often presents with primary abdominal involvement, such as abdominal masses, distension, and ascites, involving the stomach, and intestines. The bone marrow is also involved in about one-third of cases.
The BL, like other NHLs, is associated with painless lymphadenopathy, which is more common in adults rather than in children.The patients with BL may present with the constitutional symptoms, called B-symptoms, such as fatigue, night sweats, loss of weight. They are often exhausted, complain about vomiting, thirst, and dizziness. The condition may also manifest like a severe intoxication with signs of kidney failure. All symptoms are characterized by swift turnover of mature B- lymphocytes.
The other clinical features of BL are:
- Abdominal masses
- Ecchymosis and/or petechiae (as a result of thrombocytopenia) “dot-like” skin hemorrhage
- Meningeal signs (from CNS disease), confusion, headaches, impairment of eye sight, and paraplegia.
- Excisional biopsy (important for confirmation of diagnosis)
- Complete blood cell (CBC) count with differentials:
- In the case of the bone marrow involvement, there is pancytopenia
- Coagulation tests (prothrombin time [PT], partial thromboplastin time [PTT], and fibrinogen) in order to detect and evaluate the probability of disseminated intravascular coagulopathy (DIC).
- Serum electrolyte levels (in BL, there is hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia). Uric acid (if it is high it is evidential for high-grade malignancy), lactate dehydrogenase (LDH extremely elevated), and creatinine (kidney function tests). The abnormal serum electrolytes, a very high serum lactate dehydrogenase (LDH) levels and hyperuricemia may occur due to spontaneous tumor lysis.
- Liver function tests
- Tests for human immunodeficiency virus (HIV) and hepatitis B (HBV) infection for all patients
- Beta2 microglobulin is a sign of extension of the disease and its relapse.
- Immunophenotype and cytogenetic studies.
- Head or spinal computed tomography (CT) scanning
- Magnetic resonance imaging (MRI)
- Bone scanning and plain bone radiography
Staging of Burkitt Lymphoma
St. Jude/Murphy staging system for Burkett lymphoma
|Stage I||There is a solitary tumor (extranodal) or single anatomic area (nodal), abdomen and mediastinum are not involved in the process.|
|Stage IIR||Completely resected intraabdominal disease|
|Stage IIIA||Localized but nonresectable intra-abdominal disease|
|Stage IIIB||Widespread multiorgan abdominal disease|
|Stage IV||Any of the above with initial CNS and/or bone marrow involvement (less than 25% involvement; greater than 25% involvement is defined as L3ALL- acute lymphoblastic leukemia)|
Management of Burkitt Lymphoma
The mainstream therapy in the management of Burkitt lymphoma is chemotherapy. The common chemotherapeutic agents used to treat BL include:
- CODOX-M/IVAC (Magrath regimen) (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate / ifosfamide, etoposide, high-dose cytarabine) and the CALGB 9251 protocol-intensive and short- term therapy.
- Hyper-CVAD (modified fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone) and the Cancer and Leukemia Group B (CALGB) 8811 protocol-long-term therapy.
- Rituximab is added to the mainstream therapy.
- Urate-oxidase enzymes (rasburicase)
- Glucocorticoids (prednisone as the remedy for immunosuppression)
Autologous stem cell transplantation can be performed in the patients during early stages of the disease with promising results.
Radiotherapy and surgery are not the recommended options in Burkitt lymphoma.
As the hemopoiesis is oppressed in Burkitt lymphoma, the transfusions of the blood elements are compulsory (red blood cells or platelets) in the case of anemia and thrombocytopenia.
Intravenous antibiotics are administered for neutropenic fevers and CNS involvement.
Intravenous fluids are administered to adequately hydrate the patient and maintain high urine output in order to prevent tumor lysis syndrome.
Long-term monitoring is compulsory in case of Burkitt lymphoma as any other malignant tumors; the patients have regular checkups with their oncologist.